After a tough third quarter in which Emergent BioSolutions cut more than $100 million from its revenue guidance, the company is gaining some much-needed cash with an asset sale to Bavarian Nordic.
Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the ...
Bavarian Nordic’s repeatedly delayed phase 3 cancer vaccine trial has come crashing to a halt. The data monitoring committee ended the six-year odyssey after ruling it would be futile to keep treating ...
COPENHAGEN, Denmark, December 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 ...
Bavarian Nordic's COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster push
Bavarian Nordic has evidence its COVID-19 vaccine may hold up against omicron. With a midphase trial finding antibody titers were boosted to levels associated with a high level of protection, the ...
Pork is served in Bavarian inns mainly in two variants. One is "Schweinebraten" (roast pork), which comes from the back or shoulder of the pig and is braised in the oven. In Bavaria, it is usually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results